{
    "root": "361f7b6e-a67d-c21a-e063-6394a90ad8ba",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sulfamethoxazole and Trimethoprim",
    "value": "20250527",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORM",
            "code": "K679OBS311",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85146"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32112"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "SULFAMETHOXAZOLE",
            "code": "JE42381TNV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9332"
        },
        {
            "name": "TRIMETHOPRIM",
            "code": "AN164J8Y0X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_45924"
        }
    ],
    "indications": {
        "text": "reduce development drug-resistant bacteria maintain effectiveness sulfamethoxazole trimethoprim oral suspension , usp antibacterial drugs , sulfamethoxazole trimethoprim oral suspension , usp used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy . urinary tract infections treatment urinary tract infections due susceptible strains following organisms : escherichia coli , klebsiellaspecies , enterobacterspecies , morganella morganii , proteus mirabilisand proteus vulgaris.it recommended initial episodes uncomplicated urinary tract infections treated single effective antibacterial agent rather combination . acute otitis media treatment acute otitis media pediatric patients due susceptible strains streptococcus pneumoniaeor haemophilus influenzaewhen judgment physician sulfamethoxazole trimethoprim offers advantage antimicrobial agents . date , limited data safety repeated sulfamethoxazole trimethoprim oral suspension , usp pediatric patients two years age . sulfamethoxazole trimethoprim oral suspension , usp indicated prophylactic prolonged otitis media age . acute exacerbations chronic bronchitis adults treatment acute exacerbations chronic bronchitis due susceptible strains streptococcus pneumoniaeor haemophilus influenzaewhen physician deems sulfamethoxazole trimethoprim oral suspension , usp could offer advantage single antimicrobial agent . shigellosis treatment enteritis caused susceptible strains shigella flexneriand shigella sonneiwhen antibacterial therapy indicated . pneumocystis jiroveci pneumonia treatment documented pneumocystis jiroveci pneumonia prophylaxis p. jiroveci pneumonia individuals immunosuppressed considered increased risk developing p. jiroveci pneumonia . traveler 's diarrhea adults treatment traveler \u2019 diarrhea due susceptible strains enterotoxigenic e. coli .",
        "doid_entities": [
            {
                "text": "otitis media (DOID:10754)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10754"
            },
            {
                "text": "chronic bronchitis (DOID:6132)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6132"
            },
            {
                "text": "shigellosis (DOID:12385)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12385"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "diarrhea (DOID:13250)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13250"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute otitis media",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_279888"
            }
        ]
    },
    "contraindications": {
        "text": "sulfamethoxazole trimethoprim oral suspension contraindicatedin pediatric patients less 2 months age . urinary tract infections shigellosis adults pediatric patients , acute otitis media children adults usual adult treatment urinary tract infections four teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim oral suspension every 12 hours 10 14 days . identical daily used 5 days treatment shigellosis . children recommended dose children urinary tract infections acute otitis media 40 mg/kg sulfamethoxazole 8 mg/kg trimethoprim per 24 hours , given two divided doses every 12 hours 10 days . identical daily used 5 days treatment shigellosis . following table guideline attainment : children 2 months age older : weight dose\u2013every 12 hours lb kg teaspoonfuls 22 10 1 ( 5 ml ) 44 20 2 ( 10 ml ) 66 30 3 ( 15 ml ) 88 40 4 ( 20 ml ) patients impaired renal function renal function impaired , reduced employed using following table : creatinine clearance ( ml/min ) recommended regimen 30 usual standard regimen 15 30 \u00bd usual regimen 15 recommended acute exacerbations chronic bronchitis adults usual adult treatment acute exacerbations chronic bronchitis four teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim oral suspension every 12 hours 14 days . pneumocystis jiroveci pneumonia reatment adults children recommended treatment patients documented pneumocystis jiroveci pneumonia 75 100 mg/kg sulfamethoxazole 15 20 mg/kg trimethoprim per 24 hours given equally divided doses every 6 hours 14 21 days . 11the following table guideline upper limit : weight dose\u2013every 6 hours lb kg teaspoonfuls 18 8 1 ( 5 ml ) 35 16 2 ( 10 ml ) 53 24 3 ( 15 ml ) 70 32 4 ( 20 ml ) 88 40 5 ( 25 ml ) 106 48 6 ( 30 ml ) 141 64 8 ( 40 ml ) 176 80 10 ( 50 ml ) lower limit dose ( 75 mg/kg sulfamethoxazole 15 mg/kg trimethoprim per 24 hours ) administer 75 % dose table . prophylaxis adults recommended prophylaxis adults four teaspoonfuls ( 20 ml ) suspension daily . 12 children children , recommended dose 750 mg/m 2/day sulfamethoxazole 150 mg/m 2/day trimethoprim given orally equally divided doses twice day , 3 consecutive days per week . total daily dose exceed 1600 mg sulfamethoxazole 320 mg trimethoprim . 13the following table guideline attainment children : body surface area dose\u2013every 12 hours ( 2 ) teaspoonfuls 0.26 \u00bd ( 2.5 ml ) 0.53 1 ( 5 ml ) 1.06 2 ( 10 ml ) traveler \u2019 diarrhea adults treatment traveler \u2019 diarrhea , usual adult four teaspoonfuls ( 20 ml ) suspension every 12 hours 5 days .",
        "doid_entities": [
            {
                "text": "shigellosis (DOID:12385)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12385"
            },
            {
                "text": "otitis media (DOID:10754)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10754"
            },
            {
                "text": "chronic bronchitis (DOID:6132)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6132"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "diarrhea (DOID:13250)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13250"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute otitis media",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_279888"
            }
        ]
    },
    "warningsAndPrecautions": "sulfamethoxazole trimethoprim oral suspension , uspcontains 200 mg sulfamethoxazole 40 mg trimethoprim teaspoonful ( 5 ml ) . available pink , cherry-flavored syrup suspension . ndc 17856-0496-01 sulfamethoxazole/trimeth 200/40mg/5ml - 5 ml cup 72 ct ud ndc 17856-0496-02 sulfamethoxazole/trimeth 200/40mg/5ml - 10 ml cup 72 ct ud ndc 17856-0496-03 sulfamethoxazole/trimeth 200/40mg/5ml - 20 ml cup 50 ct ud store 20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) [ usp controlled room temperature ] protect light . shake well using . dispense tight , light-resistant container defined usp , child-resistant closure ( required ) .",
    "adverseReactions": "sulfamethoxazole trimethoprim oral suspension contraindicated patients known hypersensitivity trimethoprim sulfonamides , patients history drug-induced immune thrombocytopenia trimethoprim and/or sulfonamides , patients documented megaloblastic anemia due folate deficiency . sulfamethoxazole trimethoprim oral suspension contraindicated pediatric patients less 2 months age . sulfamethoxazole trimethoprim oral suspension also contraindicated patients marked hepatic damage severe renal insufficiency renal function status monitored .",
    "indications_original": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.\n \n  \n                        \n                          Urinary Tract Infections\n  \n                     \n                       For the treatment of urinary tract infections due to susceptible strains of the following organisms:\n \n  Escherichia coli, Klebsiellaspecies,\n \n  Enterobacterspecies,\n \n  Morganella morganii, Proteus mirabilisand\n \n  Proteus vulgaris.It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination.\n \n  \n                        \n                          Acute Otitis Media\n  \n                     \n                       For the treatment of acute otitis media in pediatric patients due to susceptible strains of\n \n  Streptococcus pneumoniaeor\n \n  Haemophilus influenzaewhen in the judgment of the physician sulfamethoxazole and trimethoprim\u00a0offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim oral suspension, USP in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim oral suspension, USP is not indicated for prophylactic or prolonged administration in otitis media at any age.\n \n  \n                        \n                          Acute Exacerbations of Chronic Bronchitis in Adults\n  \n                     \n                       For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of\n \n  Streptococcus pneumoniaeor\n \n  Haemophilus influenzaewhen a physician deems that sulfamethoxazole and trimethoprim oral suspension, USP could offer some advantage over the use of a single antimicrobial agent.\n \n  \n                        \n                          Shigellosis\n  \n                     \n                       For the treatment of enteritis caused by susceptible strains of\n \n  Shigella flexneriand\n \n  Shigella sonneiwhen antibacterial therapy is indicated.\n \n  \n                        \n                        \n                        Pneumocystis\u00a0 jiroveci Pneumonia\n                     \n                     \n                       For the treatment of documented\n \n  \n                        Pneumocystis\n                        jiroveci\n                     pneumonia and for prophylaxis against\n \n  P.\u00a0\n  \n   jiroveci\n                     pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing\n \n  P.\u00a0\n  \n   jiroveci\n                     pneumonia. \n  \n                     \n                     Traveler's Diarrhea in Adults \n   \n                        \n                     For the treatment of traveler\u2019s diarrhea due to susceptible strains of enterotoxigenic\n \n  E. coli.",
    "contraindications_original": "Sulfamethoxazole and trimethoprim oral suspension is contraindicatedin pediatric patients less than 2 months of age. \n   \n                     \n                     \n                          Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients, and Acute Otitis Media in Children \n   \n                     \n                     \n                     \n                        Adults \n    \n                        \n                     \n                       The usual adult dosage in the treatment of urinary tract infections is four teaspoonfuls (20 mL) sulfamethoxazole and trimethoprim oral suspension every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. \n  \n                     \n                     \n                        Children \n    \n                        \n                     \n                       The recommended dose for children with urinary tract infections or acute otitis media is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of this dosage:\n \n  \n                        \n                          Children 2 months of age or older:\n  \n                  \n                  \n                     \n                     \n                     \n                     \n                        \n                           Weight \n     \n                           \n                           Dose\u2013every 12 hours \n     \n                           \n                        \n                        \n                           lb \n     \n                           \n                           kg \n     \n                           \n                           Teaspoonfuls \n     \n                           \n                        \n                        \n                           22 \n     \n                           \n                           10 \n     \n                           \n                           1 (5 mL) \n     \n                           \n                        \n                        \n                           44 \n     \n                           \n                           20 \n     \n                           \n                           2 (10 mL) \n     \n                           \n                        \n                        \n                           66 \n     \n                           \n                           30 \n     \n                           \n                           3 (15 mL) \n     \n                           \n                        \n                        \n                           88 \n     \n                           \n                           40 \n     \n                           \n                           4 (20 mL) \n     \n                           \n                        \n                     \n                  \n                  \n                  \n                     For Patients with Impaired Renal Function \n   \n                     \n                       When renal function is impaired, a reduced dosage should be employed using the following table:\n\n \n                  \n                     \n                     \n                     \n                        \n                           Creatinine Clearance (mL/min) \n     \n                           \n                           Recommended Dosage Regimen \n     \n                           \n                        \n                        \n                           Above 30 \n     \n                           \n                           Usual standard regimen \n     \n                           \n                        \n                        \n                           15 to 30 \n     \n                           \n                           \u00bd the usual regimen \n     \n                           \n                        \n                        \n                           Below 15 \n     \n                           \n                           Use not recommended \n     \n                           \n                        \n                     \n                  \n                  \n                  \n                     Acute Exacerbations of Chronic Bronchitis in Adults \n   \n                     \n                       The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is four teaspoonfuls (20 mL) sulfamethoxazole and trimethoprim oral suspension every 12 hours for 14 days. \n  \n                     \n                     \n                        Pneumocystis Jiroveci\u00a0 Pneumonia \n   \n                        \n                        T\n                     \n                     \n                        reatment \n    \n                        \n                     \n                     \n                     Adults and Children \n   \n                     \n                       The recommended dosage for treatment of patients with documented\n \n  Pneumocystis\u00a0\n  \n   jiroveci\n                     pneumonia is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days.\n \n  11The following table is a guideline for the upper limit of this dosage:\n\n \n                  \n                     \n                     \n                     \n                     \n                        \n                           Weight \n     \n                           \n                           Dose\u2013every 6 hours \n     \n                           \n                        \n                        \n                           lb \n     \n                           \n                           kg \n     \n                           \n                           Teaspoonfuls \n     \n                           \n                        \n                        \n                           18 \n     \n                           \n                           8 \n     \n                           \n                           1 (5 mL) \n     \n                           \n                        \n                        \n                           35 \n     \n                           \n                           16 \n     \n                           \n                           2 (10 mL) \n     \n                           \n                        \n                        \n                           53 \n     \n                           \n                           24 \n     \n                           \n                           3 (15 mL) \n     \n                           \n                        \n                        \n                           70 \n     \n                           \n                           32 \n     \n                           \n                           4 (20 mL) \n     \n                           \n                        \n                        \n                           88 \n     \n                           \n                           40 \n     \n                           \n                           5 (25 mL) \n     \n                           \n                        \n                        \n                           106 \n     \n                           \n                           48 \n     \n                           \n                           6 (30 mL) \n     \n                           \n                        \n                        \n                           141 \n     \n                           \n                           64 \n     \n                           \n                           8 (40 mL) \n     \n                           \n                        \n                        \n                           176 \n     \n                           \n                           80 \n     \n                           \n                           10 (50 mL) \n     \n                           \n                        \n                     \n                  \n                  \n                  For the lower limit dose (75 mg/kg sulfamethoxazole and 15 mg/kg trimethoprim per 24 hours) administer 75% of the dose in the above table. \n  \n                     \n                     \n                        Prophylaxis \n    \n                        \n                     \n                     \n                     Adults \n   \n                     \n                       The recommended dosage for prophylaxis in adults is four teaspoonfuls (20 mL) of the suspension daily.\n \n  12\n                     \n                     \n                        \n                          Children \n   \n                     \n                       For children, the recommended dose is 750 mg/m\n \n  2/day sulfamethoxazole with 150 mg/m\n \n  2/day trimethoprim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 1600 mg sulfamethoxazole and 320 mg trimethoprim.\n \n  13The following table is a guideline for the attainment of this dosage in children:\n\n \n                  \n                     \n                     \n                     \n                        \n                           Body Surface Area \n     \n                           \n                           Dose\u2013every 12 hours \n     \n                           \n                        \n                        \n                           (m\n    \n     2) \n     \n                           \n                           Teaspoonfuls \n     \n                           \n                        \n                        \n                           0.26 \n     \n                           \n                           \u00bd (2.5 mL) \n     \n                           \n                        \n                        \n                           0.53 \n     \n                           \n                           1 (5 mL) \n     \n                           \n                        \n                        \n                           1.06 \n     \n                           \n                           2 (10 mL) \n     \n                           \n                        \n                     \n                  \n                  \n                     Traveler\u2019s Diarrhea in Adults \n   \n                     \n                       For the treatment of traveler\u2019s diarrhea, the usual adult dosage is four teaspoonfuls (20 mL) of the suspension every 12 hours for 5 days.",
    "warningsAndPrecautions_original": "Sulfamethoxazole and Trimethoprim Oral Suspension, USPcontains 200 mg sulfamethoxazole and 40 mg trimethoprim in each teaspoonful (5 mL). Available as a pink, cherry-flavored syrup suspension.\n\n \n                  \n                  NDC 17856-0496-01 SULFAMETHOXAZOLE/TRIMETH 200/40MG/5ML - 5 ML CUP 72 ct UD\n                  NDC 17856-0496-02\u00a0SULFAMETHOXAZOLE/TRIMETH 200/40MG/5ML - 10 ML CUP 72 ct UD\n                  NDC 17856-0496-03\u00a0SULFAMETHOXAZOLE/TRIMETH 200/40MG/5ML - 20 ML CUP 50 ct UD\n                  \n                     \n                          Store at\n  20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [see USP Controlled Room Temperature] and protect from light. \n  \n                       SHAKE WELL BEFORE USING. \n  \n                       Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).",
    "adverseReactions_original": "Sulfamethoxazole and trimethoprim oral suspension is contraindicated in patients with a known hypersensitivity to trimethoprim or sulfonamides, in patients with a history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides, and in patients with documented megaloblastic anemia due to folate deficiency. \n  \n                       Sulfamethoxazole and trimethoprim oral suspension is contraindicated in pediatric patients less than 2 months of age. Sulfamethoxazole and trimethoprim oral suspension is also contraindicated in patients with marked hepatic damage or with severe renal insufficiency when renal function status cannot be monitored.",
    "drug": [
        {
            "name": "Sulfamethoxazole and Trimethoprim",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9332"
        }
    ]
}